公开(公告)号：US20240360082A1

公开(公告)日：2024-10-31

申请号：US18291083

申请日：2022-07-22

申请人： NOVARTIS AG

发明人： Graham Charles BLOOMFIELD ,  Matthew James HESSE ,  Richard Yichong HUANG ,  Michael Robert MASER ,  James Clifford SUTTON ,  Benjamin Robert TAFT ,  David Charles TULLY

IPC分类号： C07D213/82 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D401/10 ,  C07D401/12 ,  C07D405/10 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D493/08 ,  C07D493/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10

CPC分类号： C07D213/82 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D401/10 ,  C07D401/12 ,  C07D405/10 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D493/08 ,  C07D493/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10

摘要： The disclosure provides compounds of Formula (I): (I) as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.

公开(公告)号：US12121524B2

公开(公告)日：2024-10-22

申请号：US16962441

申请日：2019-01-16

申请人： VERTEX PHARMACEUTICALS INCORPORATED

发明人： Marc Saul Weinberg ,  Diego Sebastian D'Astolfo ,  Sudipta Mahajan

IPC分类号： A61K31/5377 ,  A61K9/00 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/7088 ,  A61K38/46 ,  A61P43/00 ,  C07D413/12 ,  C12N9/22 ,  C12N15/11

CPC分类号： A61K31/5377 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/7088 ,  A61K38/465 ,  A61P43/00 ,  C07D413/12 ,  C12N9/22 ,  C12N15/11 ,  C12N2310/20 ,  C12N2320/31 ,  C12N2320/32 ,  C12N2320/35 ,  C12N2800/80

摘要： The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various diseases, conditions, or disorders.

公开(公告)号：US20240342400A1

公开(公告)日：2024-10-17

申请号：US18626527

申请日：2024-04-04

申请人： Flik Therapeutics, Inc.

发明人： Brendan Heiden

IPC分类号： A61M11/04 ,  A61K31/137 ,  A61K31/465 ,  A61K31/498 ,  A61M15/06 ,  G16H20/10

CPC分类号： A61M11/042 ,  A61K31/137 ,  A61K31/465 ,  A61K31/498 ,  A61M11/047 ,  A61M15/06 ,  G16H20/10

摘要： A smoking cessation system may include a nicotine delivery device to deliver a mixture in an aerosol form to a user, through pulmonary delivery. The mixture may include nicotine. The system may be prescription, over-the-counter, or non-prescription based. The smoking cessation system may also include a health hub to communicate with the nicotine delivery device and to control operation of the nicotine delivery device based on information. Such information may include, for example, information relating to the use of the nicotine delivery device by the user. One or more additional devices (e.g., a continuous monitoring device that detects nicotine content and use, including through metabolites such as cotinine or carbon monoxide) may communicate one or more items of the information to the health hub for the purpose of assisting the user to quit smoking.

公开(公告)号：US20240327381A1

公开(公告)日：2024-10-03

申请号：US18435117

申请日：2024-02-07

申请人： Celgene Corporation ,  Bristol-Myers Squibb Company

发明人： Laura Akullian D'Agostino ,  Godwin Kumi ,  Haibo Liu

IPC分类号： C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/498 ,  C07D401/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/00 ,  C07D471/04

CPC分类号： C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/498 ,  C07D401/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/00 ,  C07D471/04

摘要： Provided herein are compounds and compositions thereof for degrading an engineered polypeptide in a cell. In some embodiments, the compounds and compositions are provided for treatment of cancer.

公开(公告)号：US12102628B2

公开(公告)日：2024-10-01

申请号：US17706225

申请日：2022-03-28

申请人： Seinda Pharmaceutical Guangzhou Corporation

发明人： Hui Ouyang ,  Yong Qiu

IPC分类号： A61P27/02 ,  A61K9/00 ,  A61K31/06 ,  A61K31/216 ,  A61K31/222 ,  A61K31/24 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/439 ,  A61K31/4406 ,  A61K31/46 ,  A61K31/498 ,  A61K31/551 ,  A61K31/5513 ,  A61P27/10 ,  C07C217/20 ,  C07C219/10 ,  C07D213/04 ,  C07D235/02 ,  C07D403/04 ,  C07D403/12 ,  C07D471/08 ,  C07D487/04 ,  C07D491/18

CPC分类号： A61K31/46 ,  A61K9/0048 ,  A61K31/24 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/498 ,  A61K31/551 ,  A61P27/10

摘要： Compositions and methods useful in slowing, inhibiting, or regressing the progression of myopia, while minimizing pupil dilation and light sensitivity are provided herein. Provided compositions can include a muscarinic receptor antagonist and a miotic agent.

公开(公告)号：US20240316039A1

公开(公告)日：2024-09-26

申请号：US18259982

申请日：2022-01-13

申请人： SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

发明人： Ajay Jaysingh KHOPADE ,  Arindam HALDER

IPC分类号： A61K31/498 ,  A61K9/00 ,  A61K9/10 ,  A61P27/06

CPC分类号： A61K31/498 ,  A61K9/0048 ,  A61K9/10 ,  A61P27/06

摘要： The present invention relates to a method of reducing elevated intraocular pressure in humans with open angle glaucoma or ocular hypertension, comprising administering brimonidine or its pharmaceutically acceptable salt. The invention also relates to a pharmaceutical composition suitable for ophthalmic use comprising brimonidine or its pharmaceutically acceptable salt.

公开(公告)号：US20240307299A1

公开(公告)日：2024-09-19

申请号：US18516480

申请日：2023-11-21

申请人： Allergan, Inc.

发明人： Yumna Shabaik ,  Jim Jiao ,  Chetan Pujara

IPC分类号： A61K9/00 ,  A61K9/107 ,  A61K31/138 ,  A61K31/498 ,  A61K31/542 ,  A61K31/568 ,  A61K31/573 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26 ,  A61K47/44

CPC分类号： A61K9/0048 ,  A61K9/107 ,  A61K9/1075 ,  A61K31/138 ,  A61K31/498 ,  A61K31/542 ,  A61K31/568 ,  A61K31/573 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26 ,  A61K47/44

摘要： Provided herein are topical ophthalmic preparations which comprise a non-aqueous, self-emulsifying system which can spontaneously give rise to either nanosized emulsions upon contact with an aqueous phase. Also provided herein are methods for the preparation of the same and their use in formulating and delivering poorly water soluble drugs.

公开(公告)号：US20240299379A1

公开(公告)日：2024-09-12

申请号：US18566008

申请日：2022-06-01

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Hugh D.C. SMYTH ,  Ashlee D. BRUNAUGH

IPC分类号： A61K31/498 ,  A61K9/00 ,  A61K31/7036

CPC分类号： A61K31/498 ,  A61K9/0075 ,  A61K31/7036

摘要： The present disclosure provides pharmaceutical compositions of clofazimine and amikacin that may be administered via inhalation. These compositions may be used to treat one or more diseases or disorders such as a bacterial infection or other lung diseases or disorders. These compositions may be made using a spray drying method that results in deposition of the clofazimine onto the amikacin.

公开(公告)号：US20240294524A1

公开(公告)日：2024-09-05

申请号：US18632638

申请日：2024-04-11

申请人： Viracta Therapeutics, Inc. ,  Millennium Pharmaceuticals, Inc.

发明人： Joseph ARNDT ,  Timothy CHAN ,  Kevin GUCKIAN ,  Gnanasambandam KUMARAVEL ,  Wen-Cherng LEE ,  Edward Yin-Shiang LIN ,  Daniel SCOTT ,  Lihong SUN ,  Jermaine THOMAS ,  Kurt VAN VLOTEN ,  Deping WANG ,  Lei ZHANG ,  Daniel ERLANSON

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/452 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  C07D213/82 ,  C07D213/85 ,  C07D241/26 ,  C07D241/28 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D417/14 ,  C07D473/34 ,  C07D487/04 ,  C07D491/052 ,  C07D498/04 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/452 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  C07D213/82 ,  C07D213/85 ,  C07D241/26 ,  C07D241/28 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D417/14 ,  C07D473/34 ,  C07D487/04 ,  C07D491/052 ,  C07D498/04 ,  C07D519/00

摘要： The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

公开(公告)号：US20240269133A1

公开(公告)日：2024-08-15

申请号：US18561405

申请日：2022-05-20

申请人： Purdue Pharma L.P.

发明人： Garth WHITESIDE ,  Stephen HARRIS

IPC分类号： A61K31/498 ,  A61K31/137 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/46 ,  A61K31/4725 ,  A61P13/10

CPC分类号： A61K31/498 ,  A61K31/137 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/46 ,  A61K31/4725 ,  A61P13/10

摘要： The disclosure provides a method of treating interstitial cystitis/bladder pain syndrome in a human subject in need of such treatment, comprising administering to the human subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In certain embodiments, the method comprises administering the compound of formula (IA).